Maat Pharma SA
PAR:MAAT
Maat Pharma SA
Other Non-Cash Items
Maat Pharma SA
Other Non-Cash Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Other Non-Cash Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
M
|
Maat Pharma SA
PAR:MAAT
|
Other Non-Cash Items
€561k
|
CAGR 3-Years
91%
|
CAGR 5-Years
57%
|
CAGR 10-Years
N/A
|
|
Valneva SE
PAR:VLA
|
Other Non-Cash Items
-€63.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Innate Pharma SA
PAR:IPH
|
Other Non-Cash Items
€371k
|
CAGR 3-Years
-55%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
6%
|
||
G
|
Genfit SA
PAR:GNFT
|
Other Non-Cash Items
€535k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-47%
|
CAGR 10-Years
14%
|
|
Inventiva SA
PAR:IVA
|
Other Non-Cash Items
€5m
|
CAGR 3-Years
19%
|
CAGR 5-Years
79%
|
CAGR 10-Years
N/A
|
||
Eurobio Scientific SA
PAR:ALERS
|
Other Non-Cash Items
€451k
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
Maat Pharma SA
Glance View
Maat Pharma SA operates as a clinical-stage microbiome therapeutics company. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 43 full-time employees. The company went IPO on 2021-11-08. The firm specializes in the microbiome therapy that is aimed to treatment of Gut Microbiota alteration (Dysbiosis) using patient-specific biotherapeutics in patients with serious medical conditions. Its MaaT Microbiome Restoration Therapy (MMRB) discovery and analysis platform supports the evaluation of drug candidates, the determination of new disease targets and the identification of biomarkers for microbiome-related conditions.
See Also
What is Maat Pharma SA's Other Non-Cash Items?
Other Non-Cash Items
561k
EUR
Based on the financial report for Dec 31, 2023, Maat Pharma SA's Other Non-Cash Items amounts to 561k EUR.
What is Maat Pharma SA's Other Non-Cash Items growth rate?
Other Non-Cash Items CAGR 5Y
57%
Over the last year, the Other Non-Cash Items growth was -23%. The average annual Other Non-Cash Items growth rates for Maat Pharma SA have been 91% over the past three years , 57% over the past five years .